;PMID: 8669219
;source_file_2659.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..44] = [t:0..44]
;1)sentence:[e:50..241] = [t:50..241]
;2)section:[e:245..307] = [t:245..307]
;3)section:[e:311..394] = [t:311..394]
;4)sentence:[e:398..483] = [t:398..483]
;5)sentence:[e:484..527] = [t:484..527]
;6)sentence:[e:528..659] = [t:528..659]
;7)sentence:[e:660..759] = [t:660..759]
;8)sentence:[e:760..901] = [t:760..901]
;9)sentence:[e:902..1188] = [t:902..1188]
;10)sentence:[e:1189..1374] = [t:1189..1374]
;11)sentence:[e:1375..1473] = [t:1375..1473]
;12)sentence:[e:1474..1582] = [t:1474..1582]
;13)sentence:[e:1583..1682] = [t:1583..1682]
;14)sentence:[e:1684..1761] = [t:1684..1761]
;15)sentence:[e:1763..1915] = [t:1763..1915]
;16)sentence:[e:1917..2030] = [t:1917..2030]
;17)sentence:[e:2031..2244] = [t:2031..2244]
;18)section:[e:2248..2266] = [t:2248..2266]
;19)section:[e:2272..2286] = [t:2272..2286]
;20)section:[e:2292..2319] = [t:2292..2319]
;21)section:[e:2323..2367] = [t:2323..2367]

;section 0 Span:0..44
;Acta Anaesthesiol Belg. 1995;46(3-4):133-40.
(SEC
  (FRAG (NNP:[0..4] Acta) (NNP:[5..17] Anaesthesiol) (NNP:[18..22] Belg)
        (.:[22..23] .) (CD:[24..28] 1995) (.:[28..31] ;46)
        (-LRB-:[31..32] -LRB-) (JJ:[32..34] 3-) (CD:[34..36] 4-RRB-)
        (::[36..37] :) (CD:[37..40] 133) (CD:[40..43] -40) (.:[43..44] .)))

;sentence 1 Span:50..241
;One week treatment with cimetidine does not attenuate the cortisol response
;to a  short corticotropin test in stable intensive care patients: a
;prospective,  randomized, and controlled study.
;[74..84]:substance:"cimetidine"
;[108..116]:substance:"cortisol"
;[138..151]:substance:"corticotropin"
(SENT
  (FRAG-HLN
    (S
      (NP-SBJ
        (NP
          (NML-TMP (CD:[50..53] One) (NN:[54..58] week))
          (NN:[59..68] treatment))
        (PP (IN:[69..73] with)
          (NP (NN:[74..84] cimetidine))))
      (VP (VBZ:[85..89] does) (RB:[90..93] not)
        (VP (VB:[94..103] attenuate)
          (NP
            (NP (DT:[104..107] the) (NN:[108..116] cortisol)
                (NN:[117..125] response))
            (PP (TO:[126..128] to)
              (NP (DT:[129..130] a) (JJ:[132..137] short)
                  (NN:[138..151] corticotropin) (NN:[152..156] test))))
          (PP-LOC (IN:[157..159] in)
            (NP (JJ:[160..166] stable)
              (NML (JJ:[167..176] intensive) (NN:[177..181] care))
              (NNS:[182..190] patients))))))
    (::[190..191] :)
    (NP (DT:[192..193] a)
      (NML
        (NML (JJ:[194..205] prospective)
          (NML-1 (-NONE-:[205..205] *P*)))
        (,:[205..206] ,)
        (NML (VBN:[208..218] randomized)
          (NML-1 (-NONE-:[218..218] *P*)))
        (,:[218..219] ,) (CC:[220..223] and)
        (NML (VBN:[224..234] controlled)
          (NML-1 (NN:[235..240] study)))))
    (.:[240..241] .)))

;section 2 Span:245..307
;Spapen H, Diltoer M, Nguyen DN, Ingels G, Ramet J, Huyghens L.
(SEC
  (FRAG (NNP:[245..251] Spapen) (NNP:[252..254] H,) (NNP:[255..262] Diltoer)
        (NNP:[263..265] M,) (NNP:[266..272] Nguyen) (NNP:[273..275] DN)
        (,:[275..276] ,) (NNP:[277..283] Ingels) (NNP:[284..285] G)
        (,:[285..286] ,) (NNP:[287..292] Ramet) (NNP:[293..295] J,)
        (NNP:[296..304] Huyghens) (NNP:[305..307] L.)))

;section 3 Span:311..394
;Intensive Care Department, Academic Hospital, Vrije Universiteit Brussel, 
;Belgium.
(SEC
  (FRAG (JJ:[311..320] Intensive) (NNP:[321..325] Care)
        (NNP:[326..336] Department) (,:[336..337] ,) (NNP:[338..346] Academic)
        (NNP:[347..355] Hospital) (,:[355..356] ,) (NNP:[357..362] Vrije)
        (NNP:[363..375] Universiteit) (NNP:[376..383] Brussel) (,:[383..384] ,)
        (NNP:[386..393] Belgium) (.:[393..394] .)))

;sentence 4 Span:398..483
;Cimetidine is commonly used for stress ulcer prophylaxis in intensive care 
;patients.
;[398..408]:substance:"Cimetidine"
(SENT
  (S
    (NP-SBJ-1 (NN:[398..408] Cimetidine))
    (VP (VBZ:[409..411] is)
      (ADVP (RB:[412..420] commonly))
      (VP (VBN:[421..425] used)
        (NP-1 (-NONE-:[425..425] *))
        (PP (IN:[426..429] for)
          (NP
            (NML (NN:[430..436] stress) (NN:[437..442] ulcer))
            (NN:[443..454] prophylaxis)))
        (PP-LOC (IN:[455..457] in)
          (NP
            (NML (JJ:[458..467] intensive) (NN:[468..472] care))
            (NNS:[474..482] patients)))))
    (.:[482..483] .)))

;sentence 5 Span:484..527
;Cimetidine contains an imidazole structure.
;[484..494]:substance:"Cimetidine"
;[507..516]:substance:"imidazole"
(SENT
  (S
    (NP-SBJ (NN:[484..494] Cimetidine))
    (VP (VBZ:[495..503] contains)
      (NP (DT:[504..506] an) (NN:[507..516] imidazole) (NN:[517..526] structure)))
    (.:[526..527] .)))

;sentence 6 Span:528..659
;Similar drugs have been  shown to inhibit steroid synthesis by blocking
;cytochrome P450-dependent  reactions in the adrenal cortex.
;[536..541]:substance:"drugs"
;[570..577]:substance:"steroid"
;[600..615]:cyp450:"cytochrome P450"
(SENT
  (S
    (NP-SBJ-1 (JJ:[528..535] Similar) (NNS:[536..541] drugs))
    (VP (VBP:[542..546] have)
      (VP (VBN:[547..551] been)
        (VP (VBN:[553..558] shown)
          (NP-1 (-NONE-:[558..558] *))
          (S
            (NP-SBJ (-NONE-:[558..558] *))
            (VP (TO:[559..561] to)
              (VP (VB:[562..569] inhibit)
                (NP (NN:[570..577] steroid) (NN:[578..587] synthesis))
                (PP-MNR (IN:[588..590] by)
                  (S-NOM
                    (NP-SBJ (-NONE-:[590..590] *))
                    (VP (VBG:[591..599] blocking)
                      (NP
                        (ADJP
                          (NML (NN:[600..610] cytochrome) (NN:[611..615] P450))
                          (HYPH:[615..616] -) (JJ:[616..625] dependent))
                        (NNS:[627..636] reactions))
                      (PP-LOC (IN:[637..639] in)
                        (NP (DT:[640..643] the) (JJ:[644..651] adrenal)
                            (NN:[652..658] cortex))))))))))))
    (.:[658..659] .)))

;sentence 7 Span:660..759
;It is suggested that bolus injections of  cimetidine suppress the normal
;corticosteroid production.
;[702..712]:substance:"cimetidine"
;[733..747]:substance:"corticosteroid"
(SENT
  (S
    (NP-SBJ-1
      (NP (PRP:[660..662] It))
      (SBAR-2 (-NONE-:[662..662] *EXP*)))
    (VP (VBZ:[663..665] is)
      (VP (VBN:[666..675] suggested)
        (NP-1 (-NONE-:[675..675] *))
        (SBAR-2 (IN:[676..680] that)
          (S
            (NP-SBJ
              (NP (NN:[681..686] bolus) (NNS:[687..697] injections))
              (PP (IN:[698..700] of)
                (NP (NN:[702..712] cimetidine))))
            (VP (VBP:[713..721] suppress)
              (NP (DT:[722..725] the) (JJ:[726..732] normal)
                  (NN:[733..747] corticosteroid) (NN:[748..758] production)))))))
    (.:[758..759] .)))

;sentence 8 Span:760..901
;This might be  deleterious since a decreased cortisol response seems to be
;associated with  increased mortality during chronic severe stress.
;[805..813]:substance:"cortisol"
(SENT
  (S
    (NP-SBJ (DT:[760..764] This))
    (VP (MD:[765..770] might)
      (VP (VB:[771..773] be)
        (ADJP-PRD (JJ:[775..786] deleterious))
        (SBAR-ADV (IN:[787..792] since)
          (S
            (NP-SBJ-1 (DT:[793..794] a) (VBN:[795..804] decreased)
                      (NN:[805..813] cortisol) (NN:[814..822] response))
            (VP (VBZ:[823..828] seems)
              (S
                (NP-SBJ-1 (-NONE-:[828..828] *))
                (VP (TO:[829..831] to)
                  (VP (VB:[832..834] be)
                    (VP (VBN:[835..845] associated)
                      (NP-1 (-NONE-:[845..845] *))
                      (PP-CLR (IN:[846..850] with)
                        (NP (VBN:[852..861] increased) (NN:[862..871] mortality))))
                    (PP-TMP (IN:[872..878] during)
                      (NP (JJ:[879..886] chronic) (JJ:[887..893] severe)
                          (NN:[894..900] stress)))))))))))
    (.:[900..901] .)))

;sentence 9 Span:902..1188
;We therefore performed a  prospective, randomized, and controlled study to
;assess the effect of a  short-term continuous infusion of either cimetidine
;or ranitidine, a  non-imidazole H2-pantagonist, upon cortisol secretion in a
;cohort of  hemodynamically stable intensive care patients.
;[1042..1052]:substance:"cimetidine"
;[1056..1066]:substance:"ranitidine"
;[1075..1084]:substance:"imidazole"
;[1085..1099]:substance:"H2-pantagonist"
;[1106..1114]:substance:"cortisol"
(SENT
  (S
    (NP-SBJ (PRP:[902..904] We))
    (ADVP (RB:[905..914] therefore))
    (VP (VBD:[915..924] performed)
      (NP (DT:[925..926] a)
        (NML
          (NML (JJ:[928..939] prospective)
            (NML-1 (-NONE-:[939..939] *P*)))
          (,:[939..940] ,)
          (NML (VBN:[941..951] randomized)
            (NML-1 (-NONE-:[951..951] *P*)))
          (,:[951..952] ,) (CC:[953..956] and)
          (NML (VBN:[957..967] controlled)
            (NML-1 (NN:[968..973] study)))))
      (S-PRP
        (NP-SBJ (-NONE-:[973..973] *))
        (VP (TO:[974..976] to)
          (VP (VB:[977..983] assess)
            (NP
              (NP (DT:[984..987] the) (NN:[988..994] effect))
              (PP (IN:[995..997] of)
                (NP
                  (NP (DT:[998..999] a)
                    (NML (JJ:[1001..1006] short) (HYPH:[1006..1007] -)
                         (NN:[1007..1011] term))
                    (JJ:[1012..1022] continuous) (NN:[1023..1031] infusion))
                  (PP (IN:[1032..1034] of)
                    (NP (CC:[1035..1041] either)
                      (NP (NN:[1042..1052] cimetidine))
                      (CC:[1053..1055] or)
                      (NP
                        (NP (NN:[1056..1066] ranitidine))
                        (,:[1066..1067] ,)
                        (NP (DT:[1068..1069] a)
                          (NML (AFX:[1071..1074] non) (HYPH:[1074..1075] -)
                               (NN:[1075..1084] imidazole))
                           (NN:[1085..1087] H2) (HYPH:[1087..1088] -)
                           (NN:[1088..1099] pantagonist)))))))
              (,:[1099..1100] ,)
              (PP (IN:[1101..1105] upon)
                (NP (NN:[1106..1114] cortisol) (NN:[1115..1124] secretion))))
            (PP-LOC (IN:[1125..1127] in)
              (NP
                (NP (DT:[1128..1129] a) (NN:[1130..1136] cohort))
                (PP (IN:[1137..1139] of)
                  (NP
                    (ADJP (RB:[1141..1156] hemodynamically)
                          (JJ:[1157..1163] stable))
                    (NML (JJ:[1164..1173] intensive) (NN:[1174..1178] care))
                    (NNS:[1179..1187] patients)))))))))
    (.:[1187..1188] .)))

;sentence 10 Span:1189..1374
;Twenty patients were  consecutively enrolled following determined inclusion
;criteria and divided in  three treatment groups: 6 controls, 7 cimetidine-
;and 7 ranitidinetreated  subjects.
;[1328..1338]:substance:"cimetidine"
;[1346..1356]:substance:"ranitidine"
(SENT
  (S
    (NP-SBJ-3 (CD:[1189..1195] Twenty) (NNS:[1196..1204] patients))
    (VP (VBD:[1205..1209] were)
      (VP
        (VP
          (ADVP (RB:[1211..1224] consecutively))
          (VBN:[1225..1233] enrolled)
          (NP-3 (-NONE-:[1233..1233] *))
          (S-ADV
            (NP-SBJ (-NONE-:[1233..1233] *))
            (VP (VBG:[1234..1243] following)
              (NP (VBN:[1244..1254] determined) (NN:[1255..1264] inclusion)
                  (NNS:[1265..1273] criteria)))))
        (CC:[1274..1277] and)
        (VP (VBN:[1278..1285] divided)
          (NP-3 (-NONE-:[1285..1285] *))
          (PP (IN:[1286..1288] in)
            (NP
              (NP (CD:[1290..1295] three) (NN:[1296..1305] treatment)
                  (NNS:[1306..1312] groups))
              (::[1312..1313] :)
              (NP
                (NP (CD:[1314..1315] 6) (NNS:[1316..1324] controls))
                (,:[1324..1325] ,)
                (NP (CD:[1326..1327] 7)
                  (ADJP (NN:[1328..1338] cimetidine) (HYPH:[1338..1339] -)
                    (ADJP-1 (-NONE-:[1339..1339] *P*)))
                  (NML-2 (-NONE-:[1339..1339] *P*)))
                (CC:[1340..1343] and)
                (NP (CD:[1344..1345] 7)
                  (ADJP (NN:[1346..1356] ranitidine)
                    (ADJP-1 (VBN:[1356..1363] treated)))
                  (NML-2 (NNS:[1365..1373] subjects)))))))))
    (.:[1373..1374] .)))

;sentence 11 Span:1375..1473
;Both cimetidine (1200 mg) and ranitidine (200 mg) were administered by 
;infusion pump over 24 hrs.
;[1380..1390]:substance:"cimetidine"
;[1392..1396]:quantitative-value:"1200"
;[1397..1399]:quantitative-units:"mg"
;[1405..1415]:substance:"ranitidine"
;[1417..1420]:quantitative-value:"200"
;[1421..1423]:quantitative-units:"mg"
;[1466..1468]:quantitative-value:"24"
;[1469..1472]:quantitative-units:"hrs"
(SENT
  (S
    (NP-SBJ-1 (CC:[1375..1379] Both)
      (NP (NN:[1380..1390] cimetidine)
        (PRN (-LRB-:[1391..1392] -LRB-)
          (NP (CD:[1392..1396] 1200) (NN:[1397..1399] mg))
          (-RRB-:[1399..1400] -RRB-)))
      (CC:[1401..1404] and)
      (NP (NN:[1405..1415] ranitidine)
        (PRN (-LRB-:[1416..1417] -LRB-)
          (NP (CD:[1417..1420] 200) (NN:[1421..1423] mg))
          (-RRB-:[1423..1424] -RRB-))))
    (VP (VBD:[1425..1429] were)
      (VP (VBN:[1430..1442] administered)
        (NP-1 (-NONE-:[1442..1442] *))
        (PP-MNR (IN:[1443..1445] by)
          (NP (NN:[1447..1455] infusion) (NN:[1456..1460] pump)))
        (PP-TMP (IN:[1461..1465] over)
          (NP (CD:[1466..1468] 24) (NNS:[1469..1472] hrs)))))
    (.:[1472..1473] .)))

;sentence 12 Span:1474..1582
;A short corticotropin test was done within 24 hrs  after admission (d0) and
;repeated 7 days thereafter (d7).
;[1482..1495]:substance:"corticotropin"
;[1517..1519]:quantitative-value:"24"
;[1520..1523]:quantitative-units:"hrs"
;[1559..1560]:quantitative-value:"7"
;[1561..1565]:quantitative-units:"days"
(SENT
  (S
    (NP-SBJ-1 (DT:[1474..1475] A) (JJ:[1476..1481] short)
              (NN:[1482..1495] corticotropin) (NN:[1496..1500] test))
    (VP (VBD:[1501..1504] was)
      (VP
        (VP (VBN:[1505..1509] done)
          (NP-1 (-NONE-:[1509..1509] *))
          (PP-TMP (IN:[1510..1516] within)
            (NP
              (NP (CD:[1517..1519] 24) (NNS:[1520..1523] hrs))
              (PP (IN:[1525..1530] after)
                (NP (NN:[1531..1540] admission)))
              (PRN (-LRB-:[1541..1542] -LRB-)
                (NP (NN:[1542..1544] d0))
                (-RRB-:[1544..1545] -RRB-)))))
        (CC:[1546..1549] and)
        (VP (VBN:[1550..1558] repeated)
          (NP-1 (-NONE-:[1558..1558] *))
          (NP-TMP
            (NP
              (NP (CD:[1559..1560] 7) (NNS:[1561..1565] days))
              (ADVP (RB:[1566..1576] thereafter)))
            (PRN (-LRB-:[1577..1578] -LRB-)
              (NP (NN:[1578..1580] d7))
              (-RRB-:[1580..1581] -RRB-))))))
    (.:[1581..1582] .)))

;sentence 13 Span:1583..1682
;On both occasions,  plasma cortisol was measured immediately before the test
;and 30 min afterwards.
;[1610..1618]:substance:"cortisol"
;[1664..1666]:quantitative-value:"30"
;[1667..1670]:quantitative-units:"min"
(SENT
  (S
    (PP (IN:[1583..1585] On)
      (NP (DT:[1586..1590] both) (NNS:[1591..1600] occasions)))
    (,:[1600..1601] ,)
    (NP-SBJ-1 (NN:[1603..1609] plasma) (NN:[1610..1618] cortisol))
    (VP (VBD:[1619..1622] was)
      (VP (VBN:[1623..1631] measured)
        (NP-1 (-NONE-:[1631..1631] *))
        (PP-TMP
          (ADVP (RB:[1632..1643] immediately))
          (IN:[1644..1650] before)
          (NP (DT:[1651..1654] the) (NN:[1655..1659] test)))
        (CC:[1660..1663] and)
        (ADVP-TMP
          (NP-ADV (CD:[1664..1666] 30) (NN:[1667..1670] min))
          (RB:[1671..1681] afterwards))))
    (.:[1681..1682] .)))

;sentence 14 Span:1684..1761
;The three treatment groups presented a normal cortisol response at d0 and
;d7.
;[1730..1738]:substance:"cortisol"
(SENT
  (S
    (NP-SBJ (DT:[1684..1687] The) (CD:[1688..1693] three)
            (NN:[1694..1703] treatment) (NNS:[1704..1710] groups))
    (VP (VBD:[1711..1720] presented)
      (NP (DT:[1721..1722] a) (JJ:[1723..1729] normal)
          (NN:[1730..1738] cortisol) (NN:[1739..1747] response))
      (PP-TMP (IN:[1748..1750] at)
        (NP (NN:[1751..1753] d0) (CC:[1754..1757] and) (NN:[1758..1760] d7))))
    (.:[1760..1761] .)))

;sentence 15 Span:1763..1915
;Peak cortisol levels after stimulation did not show any significant
;difference  for both the cimetidine and the ranitidine group, either at d0 or
;at d7.
;[1768..1776]:substance:"cortisol"
;[1856..1866]:substance:"cimetidine"
;[1875..1885]:substance:"ranitidine"
(SENT
  (S
    (NP-SBJ
      (NP (JJ:[1763..1767] Peak) (NN:[1768..1776] cortisol)
          (NNS:[1777..1783] levels))
      (PP-TMP (IN:[1784..1789] after)
        (NP (NN:[1790..1801] stimulation))))
    (VP (VBD:[1802..1805] did) (RB:[1806..1809] not)
      (VP (VB:[1810..1814] show)
        (NP (DT:[1815..1818] any) (JJ:[1819..1830] significant)
            (NN:[1831..1841] difference))
        (PP (IN:[1843..1846] for)
          (NP (CC:[1847..1851] both)
            (NP (DT:[1852..1855] the) (NN:[1856..1866] cimetidine)
              (NML-1 (-NONE-:[1866..1866] *P*)))
            (CC:[1867..1870] and)
            (NP (DT:[1871..1874] the) (NN:[1875..1885] ranitidine)
              (NML-1 (NN:[1886..1891] group)))))
        (,:[1891..1892] ,)
        (PP-TMP (CC:[1893..1899] either)
          (PP (IN:[1900..1902] at)
            (NP (NN:[1903..1905] d0)))
          (CC:[1906..1908] or)
          (PP (IN:[1909..1911] at)
            (NP (NN:[1912..1914] d7))))))
    (.:[1914..1915] .)))

;sentence 16 Span:1917..2030
;Moreover, this response at d0 and d7 was also not significantly different
;from  the one observed in the controls.
(SENT
  (S
    (ADVP (RB:[1917..1925] Moreover))
    (,:[1925..1926] ,)
    (NP-SBJ
      (NP (DT:[1927..1931] this) (NN:[1932..1940] response))
      (PP-TMP (IN:[1941..1943] at)
        (NP (NN:[1944..1946] d0) (CC:[1947..1950] and) (NN:[1951..1953] d7))))
    (VP (VBD:[1954..1957] was)
      (ADVP (RB:[1958..1962] also))
      (RB:[1963..1966] not)
      (ADJP-PRD (RB:[1967..1980] significantly) (JJ:[1981..1990] different)
        (PP (IN:[1991..1995] from)
          (NP
            (NP-1 (DT:[1997..2000] the) (CD:[2001..2004] one))
            (VP (VBN:[2005..2013] observed)
              (NP-1 (-NONE-:[2013..2013] *))
              (PP-LOC (IN:[2014..2016] in)
                (NP (DT:[2017..2020] the) (NNS:[2021..2029] controls))))))))
    (.:[2029..2030] .)))

;sentence 17 Span:2031..2244
;From this study we can conclude that one week  treatment with conventional
;intravenous doses of cimetidine does not induce  significant alterations of
;the cortisol response in hemodynamically stable ICU  patients.
;[2068..2071]:quantitative-value:"one"
;[2072..2076]:quantitative-units:"week"
;[2127..2137]:substance:"cimetidine"
;[2186..2194]:substance:"cortisol"
(SENT
  (S
    (PP (IN:[2031..2035] From)
      (NP (DT:[2036..2040] this) (NN:[2041..2046] study)))
    (NP-SBJ (PRP:[2047..2049] we))
    (VP (MD:[2050..2053] can)
      (VP (VB:[2054..2062] conclude)
        (SBAR (IN:[2063..2067] that)
          (S
            (NP-SBJ
              (NP
                (NML (CD:[2068..2071] one) (NN:[2072..2076] week))
                (NN:[2078..2087] treatment))
              (PP (IN:[2088..2092] with)
                (NP
                  (NP (JJ:[2093..2105] conventional)
                      (JJ:[2106..2117] intravenous) (NNS:[2118..2123] doses))
                  (PP (IN:[2124..2126] of)
                    (NP (NN:[2127..2137] cimetidine))))))
            (VP (VBZ:[2138..2142] does) (RB:[2143..2146] not)
              (NP (VB:[2147..2153] induce)
                (NP
                  (NP (JJ:[2155..2166] significant)
                      (NNS:[2167..2178] alterations))
                  (PP (IN:[2179..2181] of)
                    (NP (DT:[2182..2185] the) (NN:[2186..2194] cortisol)
                        (NN:[2195..2203] response))))
                (PP-LOC (IN:[2204..2206] in)
                  (NP
                    (ADJP (RB:[2207..2222] hemodynamically)
                          (JJ:[2223..2229] stable))
                    (NN:[2230..2233] ICU) (NNS:[2235..2243] patients)))))))))
    (.:[2243..2244] .)))

;section 18 Span:2248..2266
;Publication Types:
(SEC
  (NP (NNP:[2248..2259] Publication) (NNP:[2260..2265] Types) (::[2265..2266] :)))

;section 19 Span:2272..2286
;Clinical Trial
(SEC
  (NP (NNP:[2272..2280] Clinical) (NNP:[2281..2286] Trial)))

;section 20 Span:2292..2319
;Randomized Controlled Trial
(SEC
  (NP (NNP:[2292..2302] Randomized) (NNP:[2303..2313] Controlled)
      (NNP:[2314..2319] Trial)))

;section 21 Span:2323..2367
;PMID: 8669219 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[2323..2327] PMID) (::[2327..2328] :) (CD:[2329..2336] 8669219)
        (NN:[2337..2338] -LSB-) (NNP:[2338..2344] PubMed) (::[2345..2346] -)
        (NN:[2347..2354] indexed) (IN:[2355..2358] for)
        (NNP:[2359..2367] MEDLINE-RSB-)))
